Recent Updates
Recently added Catalysts
ONC Positive Sentiment

Riassunto: BeOne Medicines e Revolution Medicines annunciano una collaborazione per lo sviluppo clinico e la commercializzazione regionale

Monday, August 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BeOne Medicines and Revolution Medicines have announced a multi-faceted collaboration aimed at developing and commercializing targeted therapies for RAS-dependent tumors. This partnership is expected to enhance clinical evaluations of drug combinations. Both companies are focused on advancing oncology treatments to improve patient outcomes.

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration between BeOne Medicines and Revolution Medicines announced.
  • Focus on developing targeted therapies for RAS-dependent tumors.
  • Potential for significant advancements in oncology treatments.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
3.8%
average across 5 past catalysts
Lead asset
lenvatinib
Phase 2 · Advanced Solid Tumor

Full Press Release Details

SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), azienda globale attiva nel settore oncologico, e Revolution Medicines, Inc. (Nasdaq: RVMD), azienda operante nel settore dell'oncologia clinica in fase avanzata che sviluppa terapie mirate per pazienti affetti da tumori RAS-dipendenti, oggi ha annunciato una collaborazione articolata in più parti, che comprende una collaborazione clinica volta a valutare combinazioni di farm

Frequently Asked Questions

What is the focus of the BeOne and Revolution Medicines collaboration?

The collaboration focuses on developing targeted therapies for RAS-dependent tumors.

Which companies are involved in the collaboration?

The collaboration involves BeOne Medicines and Revolution Medicines.

What type of therapies are being developed?

The collaboration aims to develop targeted therapies for oncology.

Where are BeOne Medicines and Revolution Medicines based?

Both companies are based in California.

ShareAdd on Google
Tags: ONC Viatris Investor Conferences Healthcare BeOne Medicines Revolution Medicines oncology RAS-dependent tumors clinical collaboration
Last updated: Aug 10, 2026

Biotech snapshot

Cash runway
$5098M liquidity · $0M/mo burn
Low dilution risk
Lead asset
lenvatinibPhase 2
Advanced Solid Tumor →

Catalyst track record

+15%
best trade around ONC's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ONC.

See every catalyst's timing & PoA →